MedGenome plans to use Illumina's NovaSeq X Plus to provide advanced genomics services in South Asia. The company aims to reduce the reagent cost of Human Whole Genome sequencing to USD $200 [INR 16,500] in the near future. Additionally, MedGenome has introduced KaryoSeq (or Karyotype Sequencing), Whole Genome Sequencing to diagnose prenatal and newborn conditions, alongside this acquisition.

The NovaSeq X Series produces over 20,000 whole genomes annually, offering 2.5 times the throughput of previous sequencers and shorter turnaround times. This latest sequencer aims to enhance the sustainability and accessibility of genomics on a global scale. Over the past decade, MedGenome has maintained a long-standing partnership with Illumina, continually expanding its sequencing equipment portfolio with the latest advancements and establishing itself as a leader in adopting state-of-the-art sequencing technology.

KaryoSeq offers a faster and more accurate solution for detecting small chromosomal abnormalities, including microdeletions or microduplications, that may be challenging to identify through microscopic examination alone. It is highly recommended for individuals with suspected or confirmed genetic disorders or an elevated risk of carrying chromosomal abnormalities. The objective is to deliver precise and rapid results, enabling clinicians and families to make well-informed decisions regarding inherent genetic conditions.

Dr. Vedam Ramprasad, PhD, the CEO of MedGenome, expressed -

“As pioneers in genetic testing with deep focus on scientific innovation and research, bringing NovaSeq X Plus in India will help us in making faster and accurate diagnosis. The launch of KaryoSeq further marks a significant milestone in the field of prenatal and newborn genetic testing in this part of the world, empowering clinicians with accurate and comprehensive genetic information. Traditionally, cost has played a major factor in penetrating the genetic testing market.

MedGenome has been striving to make these tests affordable to the masses while adhering to global quality standards.  MedGenome’s KaryoSeq test is another step in this direction. The test is cost-effective while providing superior diagnostic yield and accuracy in identifying deletions and gains as small as 1 megabase (1 million DNA base pairs).”

Resource - https://www.expresshealthcare.in/news/medgenome-acquires-illuminas-novaseq-x-plus/439861/